Are you or your loved ones suffering from multiple myeloma?

You may be eligible to participate in a multiple myeloma clinical trial.

Are you or your loved ones suffering from multiple myeloma? You may be eligible to participate in a multiple myeloma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Multiple Myeloma
NCT02863991 | Phase 1 phase 2 | Interventional
What you may receive

Study related treatment at no cost

Oncoceutics Inc
Sponsored by
Oncoceutics Inc

Are you or your loved ones suffering from multiple myeloma?

You may be eligible to participate in a multiple myeloma clinical trial.

Are you or your loved ones suffering from multiple myeloma? You may be eligible to participate in a multiple myeloma clinical trial.

Recruiting

Male & Female

18 +

years old

ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma. Funding Source - FDA OOPD

Available locations
The Mount Sinai Medical Center

The Mount Sinai Medical Center

Recruiting New York, NY, USA 10029-6574

Fox Chase Cancer Center

Fox Chase Cancer Center

Recruiting 333 Cottman Avenue, Philadelphia, PA, USA 19111

Interested in participating?
Oncoceutics Inc
Sponsored by Oncoceutics Inc

To get started, please choose a location